For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus FLOT yields better outcomes than FLOT alone.

A new research paper was published in Volume 16 of Genes & Cancer on May 9, 2025, titled "Evaluation of LncRNAs CBR3-AS1 and ...